Gliomas with mutations in isocitrate dehydrogenase (IDH) 1 and 2, first discovered in genomic analysis of GBM, are a molecularly distinct subtype of diffuse glioma associated with younger age of diagnosis and longer overall survival compared to IDH1/2 wild-type gliomas [15,16,17]. The gene discussed is IDH3A; the disease is central nervous system cancer.